Oneness Biotech Co Ltd - Asset Resilience Ratio
Oneness Biotech Co Ltd (4743) has an Asset Resilience Ratio of 35.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how Oneness Biotech Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Oneness Biotech Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Oneness Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oneness Biotech Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$4.19 Billion | 35.43% |
| Total Liquid Assets | NT$4.19 Billion | 35.43% |
Asset Resilience Insights
- Very High Liquidity: Oneness Biotech Co Ltd maintains exceptional liquid asset reserves at 35.43% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oneness Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Oneness Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual Asset Resilience Ratio data for Oneness Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.71% | NT$5.97 Billion ≈ $188.13 Million |
NT$13.66 Billion ≈ $430.35 Million |
-1.59pp |
| 2023-12-31 | 45.30% | NT$6.96 Billion ≈ $219.28 Million |
NT$15.36 Billion ≈ $484.04 Million |
+29.95pp |
| 2022-12-31 | 15.35% | NT$2.39 Billion ≈ $75.35 Million |
NT$15.58 Billion ≈ $490.87 Million |
-32.15pp |
| 2021-12-31 | 47.50% | NT$7.47 Billion ≈ $235.44 Million |
NT$15.73 Billion ≈ $495.61 Million |
-5.14pp |
| 2020-12-31 | 52.65% | NT$8.10 Billion ≈ $255.17 Million |
NT$15.38 Billion ≈ $484.69 Million |
+32.28pp |
| 2019-12-31 | 20.37% | NT$1.42 Billion ≈ $44.79 Million |
NT$6.98 Billion ≈ $219.90 Million |
-0.11pp |
| 2018-12-31 | 20.48% | NT$478.25 Million ≈ $15.07 Million |
NT$2.34 Billion ≈ $73.58 Million |
-15.19pp |
| 2017-12-31 | 35.67% | NT$899.36 Million ≈ $28.33 Million |
NT$2.52 Billion ≈ $79.44 Million |
-15.55pp |
| 2016-12-31 | 51.22% | NT$1.31 Billion ≈ $41.24 Million |
NT$2.56 Billion ≈ $80.52 Million |
+12.26pp |
| 2015-12-31 | 38.95% | NT$1.09 Billion ≈ $34.45 Million |
NT$2.81 Billion ≈ $88.45 Million |
-18.75pp |
| 2014-12-31 | 57.71% | NT$1.16 Billion ≈ $36.62 Million |
NT$2.01 Billion ≈ $63.46 Million |
+7.32pp |
| 2013-12-31 | 50.39% | NT$1.05 Billion ≈ $33.18 Million |
NT$2.09 Billion ≈ $65.84 Million |
+27.30pp |
| 2012-12-31 | 23.09% | NT$329.27 Million ≈ $10.37 Million |
NT$1.43 Billion ≈ $44.93 Million |
+11.10pp |
| 2011-12-31 | 11.99% | NT$166.31 Million ≈ $5.24 Million |
NT$1.39 Billion ≈ $43.71 Million |
+0.33pp |
| 2009-12-31 | 11.66% | NT$129.76 Million ≈ $4.09 Million |
NT$1.11 Billion ≈ $35.07 Million |
-- |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more